Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Moderate Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $67.6250.

Several brokerages have recently commented on DNTH. Jefferies Financial Group lifted their price target on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Truist Financial upped their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Wedbush increased their price target on Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.56% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $43,000. Seven Fleet Capital Management LP acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at $604,000. Invesco Ltd. increased its position in shares of Dianthus Therapeutics by 125.9% in the 4th quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock valued at $4,182,000 after buying an additional 56,560 shares in the last quarter. XTX Topco Ltd acquired a new stake in Dianthus Therapeutics during the 4th quarter worth $550,000. Finally, Voloridge Investment Management LLC lifted its holdings in Dianthus Therapeutics by 80.5% during the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock worth $1,627,000 after acquiring an additional 17,612 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 0.2%

Shares of NASDAQ:DNTH opened at $55.39 on Wednesday. The stock has a market capitalization of $2.39 billion, a P/E ratio of -15.92 and a beta of 1.56. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $57.50. The business has a 50-day moving average price of $47.21 and a two-hundred day moving average price of $39.92.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.